# Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

> **NCT01928771** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2681 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01928771
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-19
- **Primary completion:** 2016-04-05
- **Final completion:** 2016-04-05
- **Target enrollment:** 2681 (ACTUAL)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928771, "Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01928771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*